EXOME

all the information, none of the junk | biotech • healthcare • life sciences

MDRNA Shrinks Board of Directors

MDRNA (NASDAQ: MRNA), the Bothell, WA-based developer of RNA interference drugs, said today it has reduced its board from eight members to five as part of its cash conservation efforts. Former CEO Steven Quay, Alex Cross, and Jack Pollack are off the new board, while Bruce Thaw, Dan Peters, James Rothman, Greg Sessler, and CEO J. Michael French will remain on the board, after yesterday’s annual shareholder meeting.